Antibodies play a crucial role in the immune system, recognizing and neutralizing foreign invaders such as bacteria, viruses, and other pathogens. At Alta Stomatology, we harness the power of antibodies to develop novel therapies for oral diseases, including periodontal disease, dental caries, and oral cancers. With a team of highly experienced researchers and scientists, we can provide you with a one-stop antibody development service to target specific oral disease-causing pathogens and mechanisms. If you have any requirements or inquiries, please do not hesitate to contact us.
Our Services
Alta Stomatology utilizes state-of-the-art technologies and expertise to identify and validate novel targets for antibody development. Our team of scientists conducts thorough research to identify targets that play a key role in the pathogenesis of oral diseases, ensuring that our antibody therapies are effective and targeted toward the underlying mechanisms of disease.
Our team specializes in the discovery of lead antibody molecules through the use of cutting-edge techniques such as phage display and hybridoma technology. Then, we leverage our expertise in antibody engineering to identify high-affinity antibodies that selectively bind to the target of interest.
Once lead antibody molecules are identified, our team works to optimize their binding affinity, stability, and pharmacokinetic properties. This process ensures that the antibodies are effective in targeting and neutralizing oral disease-causing pathogens, reducing side effects, and improving overall safety profiles.
Alta Stomatology employs a comprehensive set of analytical techniques to assess critical parameters such as specificity, stability, and immunogenicity. This thorough characterization ensures that the selected lead antibodies meet the highest quality standards before advancing to the next stages of development.
Alta Stomatology offers customized services for the production process development and scale-up of antibody drugs. Our team has extensive experience in optimizing manufacturing processes to ensure the efficient and cost-effective production of antibody therapeutics, meeting the demands of large-scale production for commercialization.
Alta Stomatology can provide comprehensive antibody drug formulation development services tailored to the specific requirements of oral disease therapies. Our team focuses on optimizing the stability, solubility, and delivery of antibody drugs, ensuring their efficacy and safety in clinical applications.
The Workflow of Antibody Development
Why Choose Alta Stomatology?
- Differentiated Antibody Development for Enhanced Success Rates
We focus on antibody differentiation in antibody development, maximizing the success rate of project development through fine-tuned R&D processes and rational indication selection. By deeply understanding oral diseases, we can more accurately determine the treatment direction, ensuring that the developed antibody drugs achieve optimal effects in specific indications.
- Comprehensive Antibody Drug Development Platform
We have established a comprehensive antibody drug development platform that covers the entire process from antibody discovery, in vitro and in vivo pharmacology assessment, engineering modifications, and affinity maturation, to drug stability studies. This comprehensive platform ensures that we can fully optimize antibody performance at every critical stage, laying a solid foundation for the final drug development.
- Diversity in Antibody Development
Alta Stomatology's antibody development expertise extends beyond singular monoclonal antibody drugs. We possess profound research and development experience encompassing various antibody-derived molecules, including bispecific antibodies, modified antibodies, diagnostic antibodies, antibody-conjugated drugs, and more. This diversity enables us to offer flexible and innovative solutions tailored to specific needs, providing customers with a comprehensive range of choices.
For research use only. Not
intended for any clinical use.
Related Services
